Details

Autor(en) / Beteiligte

• SCUTO, Anna
• KUJAWSKI, Maciej
• KOWOLIK, Claudia
• KRYMSKAYA, Ludmila
• LIN WANG
• WEISS, Lawrence M
• DIGIUSTO, David
• HUA YU
• FORMAN, Stephen
• JOVE, Richard

Titel

STAT3 Inhibition Is a Therapeutic Strategy for ABC-like Diffuse Large B-Cell Lymphoma

Ist Teil von

• Cancer research (Chicago, Ill.), 2011-05, Vol.71 (9), p.3182-3188

Ort / Verlag

Philadelphia, PA: American Association for Cancer Research

Erscheinungsjahr

2011

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Persistent STAT3 signaling contributes to malignant progression in many diverse types of human cancer. STAT3 is constitutively active in activated B-cell (ABC)-like diffuse large B-cell lymphomas (DLBCL), a class of nongerminal center derived DLBCL cells for which existing therapy is weakly effective. In this report, we provide a preclinical proof of concept that STAT3 is an effective molecular target for ABC-like DLBCL therapy. Direct inhibition of STAT3 with short hairpin RNA suppressed the growth of human ABC-like DLBCL in mouse models in a manner associated with apoptosis, repression of STAT3 target genes, and inhibition of a tumor-promoting microenvironment. Together, these results suggest that STAT3 is essential to maintain the pathophysiology of ABC-like DLBCL and therefore that STAT3 inhibition may offer a promising approach in its therapy.